[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., et al. (2016) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 2, Article No. 16018. https://doi.org/10.1038/nrdp.2016.18
|
[3]
|
Zucman-Rossi, J., Villanueva, A., Nault, J.C., et al. (2015) Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 149, 1226-1239.e1224. https://doi.org/10.1053/j.gastro.2015.05.061
|
[4]
|
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
|
[5]
|
Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022.
https://doi.org/10.1002/hep.24199
|
[6]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[7]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib versus So-rafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[8]
|
Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Dou-ble-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 389, 56-66. https://doi.org/10.1016/S0140-6736(16)32453-9
|
[9]
|
Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. The New England Journal of Medi-cine, 379, 54-63. https://doi.org/10.1056/NEJMoa1717002
|
[10]
|
Zhu, A.X., Park, J.O., Ryoo, B.Y., et al. (2015) Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 16, 859-870.
https://doi.org/10.1016/S1470-2045(15)00050-9
|
[11]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[12]
|
Llovet, J.M. and Hernandez-Gea, V. (2014) Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. Clinical Cancer Research, 20, 2072-2079. https://doi.org/10.1158/1078-0432.CCR-13-0547
|
[13]
|
Llovet, J.M., Montal, R., Sia, D., et al. (2018) Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma. Nature Reviews Clinical Oncology, 15, 599-616. https://doi.org/10.1038/s41571-018-0073-4
|
[14]
|
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. https://doi.org/10.1016/j.ccell.2015.03.001
|
[15]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[16]
|
Boutros, C., Tarhini, A., Routier, E., et al. (2016) Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combina-tion. Nature Reviews Clinical Oncology, 13, 473-486. https://doi.org/10.1038/nrclinonc.2016.58
|
[17]
|
Ribas, A. (2015) Releasing the Brakes on Cancer Immunotherapy. The New England Journal of Medicine, 373, 1490-1492.
https://doi.org/10.1056/NEJMp1510079
|
[18]
|
Sharma, P., Hu-Lieskovan, S., Wargo, J.A., et al. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017
|
[19]
|
Iñarrairaegui, M., Melero, I. and Sangro, B. (2018) Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clinical Cancer Research, 24, 1518-1524. https://doi.org/10.1158/1078-0432.CCR-17-0289
|
[20]
|
Sangro, B., Gomez-Martin, C., de la Mata, M., et al. (2013) A Clinical Trial of CTLA-4 Blockade with Tremelimumab in Patients with Hepatocellular Carcinoma and Chronic Hepa-titis C. Journal of Hepatology, 59, 81-88.
https://doi.org/10.1016/j.jhep.2013.02.022
|
[21]
|
Saung, M.T., Pelosof, L., Casak, S., et al. (2021) FDA Approval Summary: Nivolumab plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist, 26, 797-806.
https://doi.org/10.1002/onco.13819
|
[22]
|
Zhu, A., Knox, J., Kudo, M., et al. (2016) Pembrolizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: Phase 2 KEYNOTE-224 Study. Annals of Oncology, 27, VI242.
https://doi.org/10.1093/annonc/mdw371.108
|
[23]
|
Finn, R., Chan, S.L., Zhu, A.X., et al. (2016) Pembrolizumab vs Best Supportive Care for Second-Line Advanced Hepatocellular Carcinoma: Randomized, Phase 3 KEYNOTE-240 Study. Annals of Oncology, 27, VI241.
https://doi.org/10.1093/annonc/mdw371.105
|
[24]
|
Kelley, R.K., Sangro, B., Harris, W., et al. (2021) Safety, Effi-cacy, and Pharmacodynamics of Tremelimumab plus Durvalumab for Patients with Unresectable Hepatocellular Carci-noma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 39, 2991-3001. https://doi.org/10.1200/JCO.20.03555
|
[25]
|
Patel, S.P. and Kurzrock, R. (2015) PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 14, 847-856. https://doi.org/10.1158/1535-7163.MCT-14-0983
|
[26]
|
Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. (2015) Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128.
https://doi.org/10.1126/science.aaa1348
|
[27]
|
Tumeh, P.C., Harview, C.L., Yearley, J.H., et al. (2014) PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature, 515, 568-571. https://doi.org/10.1038/nature13954
|
[28]
|
Crocenzi, T.S., El-Khoueiry, A.B., Yau, T.C., et al. (2017) Nivolumab (nivo) in Sorafenib (sor)-Naive and -Experienced Pts with Advanced Hepatocellular Carcinoma (HCC): CheckMate 040 Study. Journal of Clinical Oncology, 35, 4013-4013. https://doi.org/10.1200/JCO.2017.35.15_suppl.4013
|
[29]
|
Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356.
https://doi.org/10.1056/NEJMoa1709684
|
[30]
|
Kelley, R.K., Abou-Alfa, G.K., Bendell, J.C., et al. (2017) Phase I/II Study of Durvalumab and Tremelimumab in Patients with Unresectable Hepatocellular Carcinoma (HCC): Phase I Safety and Efficacy Analyses. Journal of Clinical Oncology, 35, 4073-4073. https://doi.org/10.1200/JCO.2017.35.15_suppl.4073
|
[31]
|
Finn, R.S., Aleshin, A., Zhao, D., et al. (2012) Abstract 3858: Gains in FGF19 Are Predictive of Response to the Fibroblast Growth Factor Receptor (FGFR) Small Molecule Tyrosine Kinase Inhibitor BGJ 398 in Vitro. Cancer Research, 72, 3858-3858. https://doi.org/10.1158/1538-7445.AM2012-3858
|
[32]
|
Khan, K.A. and Kerbel, R.S. (2018) Improving Immuno-therapy Outcomes with Anti-Angiogenic Treatments and Vice Versa. Nature Reviews Clinical Oncology, 15, 310-324. https://doi.org/10.1038/nrclinonc.2018.9
|
[33]
|
Fukumura, D., Kloepper, J., Amoozgar, Z., et al. (2018) Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. Nature Reviews Clinical Oncology, 15, 325-340.
https://doi.org/10.1038/nrclinonc.2018.29
|
[34]
|
Lee, C.H., Makker, V., Rasco, D., et al. (2017) A Phase 1b/2 Trial of Lenvatinib plus Pembrolizumab in Patients with Renal Cell Carcinoma. Annals of Oncology, 28, V295-V296. https://doi.org/10.1093/annonc/mdx371.002
|
[35]
|
Schulze, K., Imbeaud, S., Letouzé, E., et al. (2015) Exome Se-quencing of Hepatocellular Carcinomas Identifies New Mutational Signatures and Potential Therapeutic Targets. Nature Genetics, 47, 505-511.
https://doi.org/10.1038/ng.3252
|
[36]
|
Totoki, Y., Tatsuno, K., Covington, K.R., et al. (2014) Trans-Ancestry Muta-tional Landscape of Hepatocellular Carcinoma Genomes. Nature Genetics, 46, 1267-1273. https://doi.org/10.1038/ng.3126
|
[37]
|
Zhu, A.X., Kang, Y.-K., Yen, C.-J., et al. (2018) REACH-2: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Sorafenib. Journal of Clinical Oncology, 36, 4003. https://doi.org/10.1200/JCO.2018.36.15_suppl.4003
|
[38]
|
Smyth, M.J., Ngiow, S.F., Ribas, A., et al. (2016) Com-bination Cancer Immunotherapies Tailored to the Tumour Microenvironment. Nature Reviews Clinical Oncology, 13, 143-158. https://doi.org/10.1038/nrclinonc.2015.209
|
[39]
|
Weber, J.S., Yang, J.C., Atkins, M.B., et al. (2015) Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 33, 2092-2099. https://doi.org/10.1200/JCO.2014.60.0379
|
[40]
|
Masucci, G.V., Cesano, A., Hawtin, R., et al. (2016) Validation of Biomarkers to Predict Response to Immunotherapy in Cancer: Volume I—Pre-Analytical and Analytical Validation. The Journal for ImmunoTherapy of Cancer, 4, 76.
https://doi.org/10.1186/s40425-016-0178-1
|
[41]
|
Jiang, H., Hegde, S., Knolhoff, B.L., et al. (2016) Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy. Nature Medicine, 22, 851-860. https://doi.org/10.1038/nm.4123
|
[42]
|
Spranger, S., Bao, R. and Gajewski, T.F. (2015) Melanoma-Intrinsic β-Catenin Signalling Prevents Anti-Tumour Immunity. Nature, 523, 231-235. https://doi.org/10.1038/nature14404
|
[43]
|
Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., et al. (2016) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 2, Article No. 16018. https://doi.org/10.1038/nrdp.2016.18
|